CD86 (B70/B7-2) ON ENDOTHELIAL-CELLS CO-STIMULATES ALLOGENEIC CD4(+) T-CELLS

被引:43
作者
SEINO, K
AZUMA, M
BASHUDA, H
FUKAO, K
YAGITA, T
OKUMURA, K
机构
[1] JUNTENDO UNIV, SCH MED, DEPT IMMUNOL, BUNKYO KU, TOKYO 113, JAPAN
[2] UNIV TSUKUBA, SCH MED, DEPT SURG, TSUKUBA, IBARAKI 305, JAPAN
关键词
ANERGY; CD28; CD80 (B7 B7-1); HUMAN UMBILICAL VEIN ENDOTHELIAL CELL; MICROVASCULAR ENDOTHELIAL CELL;
D O I
10.1093/intimm/7.8.1331
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In vascularized organ transplantation, vascular endothelial cells (EC) confronting recipient T cells are potentially significant APC initiating cellular immune responses that lead to rejection. In the present study, we studied the ability of human EC to stimulate allogeneic T cells and the co-stimulatory molecules involved in this response. On both human umbilical vein endothelial cells (HUVEC) and microvascular endothelial cells (MVEC), MHC class I, intercellular adhesion molecule (ICAM)-1 and CD86 were constitutively expressed as assessed by flow cytometry, After IFN-gamma treatment, MHC class II expression was induced, and MHC class I and ICAM-1 were up-regulated, In contrast, the expression of CD86 was unchanged and CD80 was undetectable even after IFN-gamma treatment. Highly purified CD4(+) T cells proliferated in response to IFN-gamma-treated allogeneic HUVEC and MVEC, and this response was efficiently blocked by mAb to MHC class II, ICAM-1 and CD86. Furthermore, the addition of anti-CD86 mAb to the primary culture with allogeneic EC resulted in the induction of alloantigen-specific anergy. These results suggest that CD86 expressed on EC plays a critical role in initiating cellular immune responses to vascularized allografts and would be an important target for immune intervention.
引用
收藏
页码:1331 / 1337
页数:7
相关论文
共 41 条
[1]  
ADAMS PW, 1992, J IMMUNOL, V148, P3753
[2]   CD28 INTERACTION WITH B7-COSTIMULATES PRIMARY ALLOGENEIC PROLIFERATIVE RESPONSES AND CYTOTOXICITY MEDIATED BY SMALL, RESTING LYMPHOCYTES-T [J].
AZUMA, M ;
CAYABYAB, M ;
BUCK, D ;
PHILLIPS, JH ;
LANIER, LL .
JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 175 (02) :353-360
[3]   B70 ANTIGEN IS A 2ND LIGAND FOR CTLA-4 AND CD28 [J].
AZUMA, M ;
ITO, D ;
YAGITA, H ;
OKUMURA, K ;
PHILLIPS, JH ;
LANIER, LL ;
SOMOZA, C .
NATURE, 1993, 366 (6450) :76-79
[4]  
BOUSSIOTIS VA, 1993, P NATL ACAD SCI USA, V90, P11059, DOI 10.1073/pnas.90.23.11059
[5]   B70/B7-2 IS IDENTICAL TO CD86 AND IS THE MAJOR FUNCTIONAL LIGAND FOR CD28 EXPRESSED ON HUMAN DENDRITIC CELLS [J].
CAUX, C ;
VANBERVLIET, B ;
MASSACRIER, C ;
AZUMA, M ;
OKUMURA, K ;
LANIER, LL ;
BANCHEREAU, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (05) :1841-1847
[6]  
DAMLE NK, 1993, J IMMUNOL, V150, P726
[7]   UNCOVERING OF FUNCTIONAL ALTERNATIVE CTLA-4 COUNTER-RECEPTOR IN B7-DEFICIENT MICE [J].
FREEMAN, GJ ;
BORRIELLO, F ;
HODES, RJ ;
REISER, H ;
HATHCOCK, KS ;
LASZLO, G ;
MCKNIGHT, AJ ;
KIM, J ;
DU, LN ;
LOMBARD, DB ;
GRAY, GS ;
NADLER, LM ;
SHARPE, AH .
SCIENCE, 1993, 262 (5135) :907-909
[8]   CLONING OF B7-2 - A CTLA-4 COUNTER-RECEPTOR THAT COSTIMULATES HUMAN T-CELL PROLIFERATION [J].
FREEMAN, GJ ;
GRIBBEN, JG ;
BOUSSIOTIS, VA ;
NG, JW ;
RESTIVO, VA ;
LOMBARD, LA ;
GRAY, GS ;
NADLER, LM .
SCIENCE, 1993, 262 (5135) :909-911
[9]  
GEPPERT TD, 1987, J IMMUNOL, V138, P385
[10]  
GEPPERT TD, 1985, J IMMUNOL, V134, P3100